Insulin binding to its cell surface receptor activates a range of intracellular signalling cascades that ultimately result in the regulation of a number of important metabolic events within the cell [1] . Of particular importance is insulin stimulation of glucose transport and stimulation of glycogen deposition in muscle as this accounts for the bulk of insulin stimulated glucose disposal from the blood [2, 3] . Peripheral insulin resistance at the level of skeletal muscle plays an important role in the development of hyperinsulinaemia and hyperglycaemia associated with obesity [4] and non-insulin-dependent diabetes [5] . The consensus of opinion is that defects in insulin signalling lead to the reduced ability of insulin to stimulate glucose disposal into muscle in insulin resistant individuals [6, 7] . Understanding the molecular mechanisms by which insulin regulates glucose transport and glycogen storage in skeletal muscle is therefore of great importance. Insulin acutely stimulates phosphoinositide-3 (PI 3)-kinase and evidence suggests that PI 3-kinase activity is necessary [8] [9] [10] and sufficient [11, 12] for insulin stimulation of glucose transport and also necessary for insulin activation of glycogen synthase [13, 14] . Further, there is evidence to suggest that protein kinase B (PKB) is an element of the signalling cascade leading from PI 3-kinase to activation of glycogen synthase in cell culture models [15, 16] . Insulin's regulation of these pathways has not been investigated in intact human skeletal muscle. Diabetologia (1997) Summary Isolated skeletal muscle from healthy individuals was used to evaluate the role of phosphoinositide 3-kinase (PI 3-kinase) in insulin signalling pathways regulating mitogen activated protein kinase (MAP-kinase) and protein kinase-B and to investigate whether MAP-kinase was involved in signalling pathways regulating glucose metabolism. Insulin stimulated glycogen synthase activity ( ≈ 1.7 fold), increased 3-o-methylglucose transport into human skeletal muscle strips ( ≈ 2 fold) and stimulated phosphorylation of the p42 ERK-2 isoform of MAP-kinase. This phosphorylation of p42 ERK2 was not blocked by the PI 3-kinase inhibitors LY294002 and wortmannin although it was blocked by the MAPkinase kinase (MEK) inhibitor PD 98059. However, PD98059 (up to 20 m mol/l) did not block insulin activation of glycogen synthase or stimulation of 3-o-methylglucose transport. Wortmannin and LY294002 did block insulin stimulation of protein kinase-B (PKB) phosphorylation and stimulation of 3-o-methylglucose transport was inhibited by wortmannin (IC 50 ≈ 100 nmol/l). These results indicate that MAP-kinase is activated by insulin in human skeletal muscle by a PI 3-kinase independent pathway. Furthermore this activation is not necessary for insulin stimulation of glucose transport or activation of glycogen synthase in this tissue.
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Indeed studies in rabbit muscle have suggested that glycogen synthase in muscle may be activated by insulin by a separate mitogen activated protein (MAP)-kinase dependent pathway [17] . However, a number of subsequent studies have concluded that MAP-kinase is not required for insulin stimulated activation of glycogen synthase in a range of cell culture systems (for review see [18] ). These studies have not investigated the role of MAP-kinase in skeletal muscle but have assumed that the mechanism by which insulin stimulates glycogen synthase is conserved in all cell types. Given that the original scheme for insulin regulating glycogen synthase via a MAP-kinase dependent pathway was based on evidence obtained in skeletal muscle we have investigated the role of MAP-kinase in insulin signalling pathways regulating glucose metabolism in human skeletal muscle. We have also investigated the role of PI 3-kinase in pathways leading to the activation of MAP-kinase and PKB. Subjects. Muscle specimens were obtained from the vastus lateralis portion of the quadriceps femoris muscle from 19 healthy male subjects (age 28.4 ± 0.7 years, weight 76.6 ± 2.1 kg, height 181.3 ± 1.9 cm and body mass index 23.4 ± 0.4 kg/m 2 , fasting glucose 4.9 ± 0.2 mmol/l and serum insulin 41.4 ± 2.4 pmol). None of the subjects were taking any medication. The nature, purpose and possible risks of the study were reviewed and approved by the ethical committee of the Karolinska Institute and were carefully explained to each individual before they gave their consent to participate. Following an overnight fast the subjects reported to the laboratory at 08.30 hours. A local anaesthetic (prilocain hydrochloride 10 mg/ml) was administered subcutaneously 15 cm above the proximal border of the patella and a 4 cm incision was made. Two muscle specimens (250 mg each) were excised for in vitro incubation and smaller muscle strips were prepared as described by Zierath [19] .
Materials and methods

Materials
Stimulation of muscle and determination of 3-o-methylglucose transport. After preparation, the smaller muscle strips (approximately 20 mg) were incubated at 35°C for 10 min in a recovery solution containing oxygenated Krebs-Henseleit buffer supplemented with 10 mmol/l (HEPES), 38 mmol/l mannitol, 2 mmol/ l pyruvate and 0.1 % BSA. The strips were subsequently incubated with inhibitors and insulin as indicated in the figure legends. For measurements of 3-o-methylglucose transport the buffer contained 5 mmol/l 3-o-( 3 H)methylglucose and 35 mmol/l ( 14 C)mannitol. The incubations were terminated by snap freezing the strip in liquid nitrogen and rapidly homogenising in ice cold homogenisation buffer containing 100 mmol/l NaF and 10 mmol/l EDTA. Cell debris were removed by centrifugation at 5000 × g for 1 min. 3-0-methylglucose transport was calculated as previously described [20] .
Assessment of glycogen synthase activity. Glycogen synthase activity ratio was determined in precleared muscle homogenates essentially as previously described [21] using 6 mmol/l Uridine-diphospho-glucose in the presence and absence of 7.5 mmol/l glucose 6-phosphate.
Assessment of Map-kinase activation. MAP-kinase activation was assessed using a gel mobility shift assay in which samples were run on SDS-PAGE and immunoblotted with the MAPkinase polyclonal antiserum or the phospho-specific MAP-kinase antiserum followed by 125 I-protein A. Bands were quantitated on a Bas2000 phosphoimager. For band shift experiments the results are expressed as percentage of the total doublet signal present in the upper band (phosphorylated active form).
Statistical analysis. Statistical differences between treatments were analysed using the Student's paired t-test.
Results
Insulin stimulation of MAP-kinase. The MAP-kinase antiserum used in the current study recognised both the phosphorylated and unphosphorylated forms of p42/p44 (ERK-2/ERK-1) MAP-kinase in 3T3-L1 adipocytes although the p44 isoform was undetectable in the human muscle preparations (Fig. 1 a) . The antiserum detected a doublet in unstimulated muscle corresponding to phosphorylated (upper band) and unphosphorylated (lower band) forms of p42-ERK2 (Fig. 1 a) . Using this method of assessing MAP-kinase phosphorylation it was found that approximately half of the p42 ERK2 existed in the phosphorylated form in unstimulated muscle strips. In vitro stimulation of human skeletal muscle strips with insulin caused an increase in the level of phosphorylation of p42 ERK-2 as shown by decreased mobility on SDS-PAGE ( Fig. 1 a) . This was confirmed using an antibody which only recognises the phosphorylated forms of p42/p44 (ERK-2/ERK-1) MAP-kinase. This antibody recognised a single band in human muscle lysates ( Fig. 1 b) which corresponded to the upper band of the p42 ERK2 doublet recognised by the MAP-kinase antiserum. No band corresponding to p44 ERK1 was recognised by the phospho-specific MAP-kinase antiserum although such a band was clearly observed in 3T3-L1 adipocytes (data not shown). This antiserum also confirmed that there was significant phosphorylation of p42 ERK2 in unstimulated muscle and using the combined data obtained from blotting four separate muscle strips we find the amount of phosphorylated p42 ERK2 approximately doubled with insulin stimulation (Fig. 1 c) . This is consistant with the results from the bandshift experiments which show that the proportion of p42 ERK-2 in the phosphorylated state was 58.7 ± 2.9 % (n = 25, mean ± SEM) in unstimulated muscle strips and this rose to 76.9 ± 1.5 % (n = 21) (p < 0.001) after 30 min stimulation with insulin indicating activation of p42 ERK-2 ( Fig. 1 b) . The enzyme activity associated with immunoprecipitates using this MAP-kinase antibody from unstimulated and insulin stimulated muscle closely paralleled the results seen in phospho specific MAP-kinase blots and the bandshift assays (data not shown).
The insulin induced increase in the amount of phosphorylated p42 ERK-2 was not affected by the PI 3-kinase inhibitor LY294002 at a concentration of 30 m mol/l. Further, insulin caused a similar increase in p42 ERK-2 phosphorylation in the presence of 50 and 500 nmol/l wortmannin. These increases were consistantly found and while the increases over basal did not reach statistical significance (p = 0.09 and 0.08, respectively), neither were they significantly different from the insulin stimulated levels of phosphorylation (p = 0.30 and 0.21, (Fig. 2) . Insulin stimulated PI 3-kinase activity is completely blocked by wortmannin at 50 nmol/l and LY294002 at concentrations above 10 m mol/l [9, 10] . Therefore, these findings indicate that PI 3-kinase activity is not required for insulin's stimulation of the MAP-kinase cascade in human skeletal muscle. However, preincubation with 10 m mol/l of the MEK inhibitor PD 98059 blocked the insulin induced increase in the level of p42 ERK-2 phosphorylation and at 20 m mol/l PD98059 actually reduced the level of p42 ERK-2 phosphorylation to below that seen in unstimulated muscle (Fig. 2) . This indicated that PD98059 was blocking the insulin stimulated activation of the Map-kinase cascade in human skeletal muscle.
Insulin stimulation of glycogen synthase.
In the current study insulin stimulated the glycogen synthase activity ratio approximately 1.7-fold. This stimulation was not blocked by PD98059 at concentrations of either 10 or 20 m mol/l (Fig. 3) . However 20 m mol/l PD98059 completely blocks insulin's ability to stimulate p42 ERK-2 phosphorylation in the current study and previous studies have also reported that concentrations of PD98059 as low as 3 m mol/l block insulin stimulation of ERK activity [22] .
Insulin stimulation of glucose transport. In the current study insulin stimulated 3-o-methylglucose uptake more than 2-fold which is in good agreement with previous studies in isolated human muscle strips [5] . At concentrations shown to block insulin stimulated phosphorylation of p42 ERK-2, PD98059 did not significantly reduce the level of insulin stimulation of 3-o-methylglucose transport (Fig. 4) . However, wortmannin reduced insulin stimulation of 3-o-methylglucose transport in a dose-dependent manner with an IC 50 ≈ 100 nmol/l (Fig. 5) .
Insulin stimulation of protein kinase-B phosphorylation.
Insulin caused a decrease in the mobility of PKB in an SDS-PAGE system (Fig. 6) . Previous studies have shown that this is due to phosphorylation of PKB on serine and threonine and that this is associated with activation of the enzyme [15] . Both wortmannin (250 nmol/l) and LY294002 (8 m mol/l) completely blocked the insulin induced mobility shift (Fig. 6 ) 
Discussion
The current study provides the first investigation of the involvement of PI 3-kinase in insulin signalling to PKB and the MAP-kinase cascade in human skeletal muscle. The results of the current studies demonstrate that insulin is able to stimulate phosphorylation of MAP-kinase in human skeletal muscle. Increased phosphorylation of MAP-kinase is tightly associated with an increase in enzyme activity [23] and we find a similar relationship in human skeletal muscle. Using two independent antibodies we have not able to detect significant levels of p44 ERK-2 in human skeletal muscle strips. However, the p42 ERK-2 was readily detectable and was consistently partially phosphorylated in unstimulated human muscle strips. A similar partial phosphorylation of MAP-kinase isoforms has also previously been observed in in vitro incubations of rodent muscle [24, 25] . The reason for this basal phosphorylation in muscle is not entirely clear, although the muscle strips are used immediately after preparation and are thus not quiescent. Therefore, it is possible that the stimulatory effects of the in vivo milieu of growth factors present in the bloodstream prior to excision may contribute to this effect. Exercise also stimulates MAP-kinase activity in rodent muscle [24] raising the possibility that contraction has also contributed to the basal level of p42 ERK-2 phosphorylation in the human muscle.
The finding that the MEK inhibitor PD 98059 is able to block insulin stimulation of p42 ERK-2 phosphorylation indicates that insulin stimulation of the MAP-kinase cascade is being blocked by this inhibitor. These results are entirely consistent with results obtained in cell culture models [22, 26] . However, high concentrations of two separate PI 3-kinase inhibitors, wortmannin and LY294002, were unable to block the insulin induced phosphorylation of p42-ERK-2 indicating that PI 3-kinase activity is not required for this process in our system. This is somewhat in contrast to the situation in cultured L6 myoblasts [27] and in primary cultures of human myoblasts [16] where 100 nmol/l wortmannin largely blocks insulin-like growth factor (IGF)-1 and insulin stimulation on p42-ERK-2. The reason for this difference is not clear, but it suggests that the ability of PI 3-kinase to regulate MAP-kinase activity becomes decoupled during differentiation from myoblasts to myotube.
In the current study wortmannin completely blocked the ability of insulin to stimulate glucose uptake in a dose dependent manner. The ED 50 for this effect is around 100 nmol/l which is an order of magnitude higher than insulin's inhibitory effects on glucose transport in isolated adipocytes and cell culture models [9, 10] . Similar observations have been made in rodent muscle where 100 nmol/l wortmannin is insufficient to completely block insulin stimulation of glucose uptake into rat muscle [28, 29] . The reason for this is not clear but wortmannin is known to be labile and the differences in efficacy could be due to increased degradation of wortmannin in muscle. Alternatively these differences could be due to differences in uptake kinetics of wortmannin in muscle as muscle strips are used in the assays and these are composed of multiple layers of cells. In contrast, in isolated adipocytes and cell culture systems, the inhibitor has direct access to the cells. However, even at 100 nmol/l wortmannin is thought to be a highly specific PI 3-kinase inhibitor [for review see 30, 31] . Therefore, the findings of the current study are entirely consistant with PI 3-kinase being an essential element of signalling cascades leading from the insulin receptor to glucose transporter translocation in human skeletal muscle.
Concentrations of PD 98059 which block insulin stimulated p42 ERK-2 activation had no effect on insulin induced activation of glycogen synthase or on insulin's ability to stimulate glucose transport into human skeletal muscle. These results indicate that activation of MAP-kinase was not necessary for insulin stimulation of glucose transport in human skeletal muscle. While previous studies have suggested that the MAP-kinase cascade is an intermediary in the transduction of signals from the insulin receptor to glycogen synthase in muscle [17] , the current findings suggest this is not the case in human skeletal muscle. In this respect the fully differentiated human skeletal muscle system behaves similarly to L6 myotubes [22] , undifferentiated human myoblasts [16] and intact rat diaphragm muscle [32] where PD 98059 blocks insulin stimulation of MAP-kinase but not of glycogen synthase. Therefore the physiological role of insulin's stimulation of the MAP kinase cascade in muscle remains elusive.
The current study also provides the first evidence that PKB is phosphorylated in response to insulin in human skeletal muscle and that this occurs in a PI 3-kinase dependent manner. This is of relevance as phosphorylation of PKB is closely associated with activation of the enzyme. PI 3-kinase inhibitors are also known to block insulin activation of glycogen synthase [13, 14] and this may involve PKB as the PKB lies between PI 3-kinase and glycogen synthase kinase 3 [15] . Lack of suitable reagents has precluded our ability to study insulin's regulation of glycogen synthase kinase 3 activity in the limited amounts of tissue available in the current studies. Further studies are required to elucidate the role of PKB and other PI 3-kinase dependent signalling molecules in the insulin stimulated signalling pathways regulating glucose metabolism in skeletal muscle.
